Alvotech’s Simponi Biosimilar Steps Into Phase III RA Study
‘ALVOFLEX’ Trial Follows Recent Phase I PK Study For AVT05 Candidate
Alvotech has marked another milestone by moving its proposed biosimilar to Simponi (golimumab) into Phase III comparison studies.
You may also be interested in...
In a busy week for Alvotech, the firm has announced an expansion of its partnership with Advanz to cover five further European biosimilars, at the same time as revealing two new pipeline assets. Meanwhile, the company has also dropped three products from an existing European partnership with Stada and has also terminated a development deal with BiosanaPharma.
China’s Bio-Thera Solutions has announced the start of Phase III trials for its BAT2506 proposed biosimilar golimumab rival to Janssen’s Simponi.
Teva and Alvotech have announced a major biosimilars alliance covering five products for the US market.